CABA241220P2500
- 0.23
- +0.01+4.55%
Cabaletta Bio Newsroom
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Cabaletta Bio Is Maintained at Overweight by Wells Fargo
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $12 to $25
Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Cabaletta Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
Cabaletta Bio's Promising Trial Results and Proactive Management Secure Buy Rating
Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $26
Cabaletta Bio Analyst Ratings
UBS Initiates Cabaletta Bio(CABA.US) With Buy Rating, Announces Target Price $10
Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $26
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
Evercore ISI Cuts Price Target on Cabaletta Bio to $15 From $25, Keeps Outperform Rating
Wells Fargo Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $20
Buy Rating Affirmed for Cabaletta Bio Amid Superior CD19 CAR T Therapy Efficacy in Autoimmune Disease Treatment
Cabaletta Bio Price Target Cut to $20.00/Share From $35.00 by Wells Fargo
Cabaletta Bio Analyst Ratings